Fingolimod Completed Phase 4 Trials for Relapsing Remitting Multiple Sclerosis (RRMS) Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02373098Fingolimod Effect on Cytokine and Chemokine Levels
NCT01534182Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
NCT01498887Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
NCT01420055Fingolimod -Response According to Coping - Evaluation
NCT01317004Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
NCT01623596Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.